Biocon-BBL Integration: Can It Unmask The Biosimilars Arm’s Intrinsic Worth?

 
• By Anju Ghangurde
  
Valuation
Biocon consolidating generics and biosimilars business (Shutterstock)

More from Deals

More from Business